US OptionsDetailed Quotes
IMMP240816C2500
- 0.10
- +0.05+100.00%
15min DelayTrading Jul 23 11:24 ET
0.10High0.08Low
0.08Open0.05Pre Close184 Volume495 Open Interest2.50Strike Price1.80KTurnover96.27%IV26.21%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.2685Delta0.6382Gamma27.48Leverage Ratio-0.0036Theta0.0003Rho7.38Eff Leverage0.0018Vega
Immutep Stock Discussion
Immutep Announces Successful Meeting With FDA On Phase III Design In Non-Small Cell Lung Cancer; TACTI-004 Registrational Trial Will Enrol ~750 Patients Regardless Of PD-L1 Expression In Order To Address The Entire 1l NSCLC Market Eligible For Anti-PD-1 Therapy
Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy, and sta...
Benzinga· 5 mins ago
LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
• Study expected to enrol first participants during Q3 CY2024
SYDNEY, AUSTRALIA – 17 July 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearanc...
No comment yet